Items Tagged ‘NOVA trial’

July 13th, 2016

Niraparib Improves Progression-Free Survival in Ovarian Cancer


The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed with ovarian cancer, and is the fifth most common cause of cancer-related deaths among women. Since there are no generalized […]

View full entry

Tags: BRCA1, BRCA2, News, niraparib, NOVA trial, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer